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Abstract
Introduction All neoplastic cells express one or more
members of a unique family of tumor-associated cell
surface ubiquinone (NADH) oxidase proteins with protein
disulfide-thiol interchange activity (ENOX2 or tNOX
proteins) that are characteristically blocked by quinone site
inhibitors with anti-cancer activity.
Methods Analyses using two-dimensional gel electropho-
resis with detection on western blots using a pan ENOX2
recombinant antibody revealed unique ENOX2 isoforms or
unique combinations of isoforms of differing molecular
weights and/or isoelectric points in sera of patients with
cancers of different cellular or tissue origins.
Results and Discussion Isoform presence provides for
broad-range cancer detection. The specific patterns and
molecular weights of the isoforms present allows for
identification of the cell type and/or tissue of origin of the
neoplasm. ENOX2 isoform presence and relative amounts
are largely independent of stage but may be proportional to
tumor burden to provide indications of response to therapy
and disease progression.
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Introduction
The ENOX (ECTO-NOX) family of cell surface proteins are
essential to the enlargement phase of plant and animal cell
growth. In order for newly divided cells to divide again, they
must first enlarge to some minimum size [1]. If enlargement
is blocked, cell division will cease and the inhibited cells
often will undergo apoptosis. The ENOX proteins oxidize
reduced pyridine nucleotides [NAD(P)H], hence they are
nicotinamide adenine dinucleotide phosphate (NAD(P)H)
oxidases or NOX proteins. Since the NOX proteins
participating in cell enlargement are located on the external
surface of the cell, they have been designated as ECTO-
NOX or ENOX proteins to distinguish them from all other
NADH oxidases such as those located on the inner surface
of the cell membrane [2] or in mitochondria.
While the activity of ENOX proteins is conveniently mea-
sured based on their ability to oxidize NADH, they are func-
tionally hydroquinone oxidases that serve as terminal oxidases
in a process whereby protons and electrons are shuttled from
the inside of the cell across the cell membrane to molecular
oxygen at the cell surface (plasma membrane electron
transport). This transport of protons and electrons involves a
membrane quinone, coenzyme Q [3], and the overall process
is thought to be essential to energize cell enlargement [4].
The ENOX proteins contain an active site involving copper
ions, carry out a protein disulfide interchange when not oxi-
dizing reduced quinones and resist proteases and other forms of
degradation. Being located on the cell surface and without
membrane anchoring domains, they are shed from the cell
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surface and appear in the serum fraction of blood and in urine
as relatively stable and readily accessible biofluid markers [5].
The constitutive form of the ENOX proteins (ENOX1 or
CNOX) is common to all cells and organisms thus far
investigated—animals, plants, bacteria, and yeasts. The
human constitutive ENOX1 has been cloned (Genbank
Accession No. EF432052).
A second subset of ENOX proteins is restricted to
cancer. These are the tumor associated ECTO-NOX (tNOX
or ENOX2) proteins [5]. Their association with the cancer
cell surface helps explain the well-known uncontrolled
growth of cancer cells. In contrast to the ENOX1 proteins
which are activated by growth factors, the cancer-associated
ENOX2 proteins are unresponsive to growth factors and
constitutively activated [6]. A defining characteristic of the
cancer-associated ENOX2 proteins is their ability to be
inhibited by drugs such as adriamycin and cis-platinum
which normally bind to DNA but also occupy quinone-
binding pockets on proteins such as ENOX2 [7]. An
ENOX2 or tNOX protein has been cloned (Genbank
Accession No. AF20788) [8] as well. As with ENOX1
proteins, ENOX2 proteins are located on the external cell
surface and are shed into the circulation. While ENOX1
proteins occur on both cancer and non-cancer cells,
ENOX2 proteins are cancer specific and are absent from
non-cancer cells. As such, ENOX2 proteins represent
attractive diagnostic and anti-cancer therapeutic targets [5].
The presence of ENOX2 in serum is due to shedding from
the patient’s cancer cells [9]. This provides a readily available
non-invasive serum or blood diagnostic marker. The anti-
tumor drug-inhibited ENOX2 activity is the first cell surface
change reported to be associated with most, possibly all,
forms of human cancer [10, 11]. However, while ENOX2
presence provides a non-invasive approach to cancer
detection, until recently it offered no indication as to cancer
type or location. Initially, detection utilized a pan-ENOX2
recombinant single chain variable region (scFv) of 12.1 [12]
antibody carrying an S tag that cross-reacted with all known
ENOX2 isoforms from solid tumors of human origin but did
not differentiate among different kinds of cancer. However,
analyses using this antibody, when combined with two
dimensional gel electrophoretic (2DGE) separations, revealed
specific ENOX2 isoforms, or patterns of isoforms, each
characteristic of a particular form of cancer. The isoforms
may result from alternative splicing events restricted to cancer
and expressed as a family of cancer-specific mRNAs and
proteins derived from the single ENOX2 gene [13].
Methods
Enriched serum proteins were concentrated for 2DGE
by nickel agarose precipitation. Nickel agarose beads
(Quiagen, Hilden, Germany, Mat. No. 1018244, 50 μl) were
added to 0.5 ml microcentrifuge tubes with 400 μl of sera
and placed on a rotary shaker overnight at 4°C. The protein
enriched beads were then collected by centrifugation at
1,000 g for 30 s. The supernatants were discarded and the
centrifugation step was repeated three times with pellets
resuspended in distilled, deionized H2O. The samples were
then resuspended in 150 μl of 7 M urea, 2 M thiourea, 2%
(w/v) CHAPS, 0.5% (w/v) ASB-14, 0.5% (v/v) Ampholytes
pH 3–10 (Bio-Rad), 0.5% (v/v) immobilized pH gradient
(IPG) buffer pH 3–10 (Amersham-Pharmacia Biotech),
65 mM dithiothreitol after which the samples were vortexed
for 1 h at room temperature. The supernatants were recovered
by removing the beads by centrifugation at 1,000 g for 30 s.
Four to six mg of protein were loaded for analysis. The
samples were electrophoresed in the first dimension by using
a commercial flatbed electrophoresis system (Ettan IPGphor
3, Amersham-Pharmacia Biotech) with IPG dry strips
(Amersham). A linear pH range of 3–10 on 7 cm IPG
strips was used. The IPG strips were rehydrated with the
samples overnight at room temperature. The strips were then
focused at 50 mA per strip and at constant voltage of 300 V
for 15 min, 600 V for 30 min and 1,000 V for 1 h. The
samples were then electrophoresed at an increasing voltage
to 4,000 V for 2 h. Finally, the strips were focused at a
constant 4,000 V for 28,000 Volt-hours. After isoelectric
focusing, the IPG strips were re-equilibrated for 30 min in
2.5% (w/v) SDS, 6 M urea, 30% (v/v) glycerol, 100 mM
Tris-HCl (pH 8.8). The strips were placed onto linear
sodium dodecyl sulfate polyacrylamide gel electrophoresis
(SDS-PAGE) gels (10% (w/v) polyacrylamide) and electro-
phoresed at a constant 250 V for 80 min. The samples were
then transferred to nitrocellulose membranes by electro-
blotting using the Bio-Rad trans-blot electrophoretic transfer
cell. The membranes were blocked using milk protein
(5% low fat dry milk) at room temperature for 1 h. Detec-
tion was with carrying an S-tag overnight at 4°C, followed
by alkaline phosphatase-linked anti-S (Novogen cat. No.
69598-3) and, after washing, detection with Western Blue
nitrotetrazolium substrate (Promega, Madison, WI; Cat No.
S3841) for 5–10 min at 4°C. Reactive proteins appeared
reddish blue. Images were scanned using Adobe Photo-
shop, and comparisons were made between cancer and non-
cancer samples analyzed in parallel. For interpretative
purposes, the blots were divided into quadrants I–IV with
unreactive serum albumin at the center (Fig. 1).
The single chain variable region recombinant antibodies
utilized in the western blot analyses were derived from
immunoglobulin G heavy and light chain variable regions
cloned using degenerative primers from hybridoma cells
producing an ENOX2-specific monoclonal antibody (MAB
12.1) [12]. The immunogen was ENOX2 isolated from sera
pooled from cancer patients. PCR amplification and the
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assembly of a single scFv cDNA with the light and heavy
chains ligated together with an appropriate linker [14]
having an S-peptide (His-Gln-Thr-Ala-Ala-Ala-Lys-Phe-
Gln-Arg-Gln-His) tag linked to the C terminus was trans-
fected into BL21(DE3) competent Escherichia coli cells
(Stratagene, La Jolla, CA, USA) according to Davis et al.
[15] and the recombinant scFv protein was expressed. The
pellet containing denatured inclusion bodies was collected
from broken cell preparations and the scFv was renatured
from the inclusion bodies according to Goldberg et al. [16].
Mr kDa 
Fig. 1 2-D gel western blot of ENOX2 isoforms comparing pooled
non-cancer (a) and pooled cancer (b) patient sera. ENOX2-enriched
from pooled cancer sera (major carcinomas) fractions (b) compared to
non-cancer (a). The approximate location of unreactive (at back-
ground) albumin is labeled for comparison. ENOX2 isoforms are
restricted to quadrants I and IV. Detection used recombinant scFv-S
(S-tag peptide: His-Gln-Thr-Ala-Ala-Ala-Lys-Phe-Gln-Arg-Gln-His)
antibody visualized with alkaline phosphatase-linked S protein (S-
AP). The >10 ENOX2 isoforms (b) of pooled sera are absent from
non-cancer (a) and are cancer site-specific as indicated in Fig. 2
Mr 
Fig. 2 Western blots of 2DGE of sera from cancer patients analyzed
individually. Cancer sites are presented in the order of decreasing
molecular weight of the major isoform present. a Cervical cancer, b
ovarian cancer, c prostate cancer, d breast cancer, e non-small cell lung
cancer, f small cell lung cancer, g pancreatic cancer, h colon cancer, i
Non-Hodgkins lymphoma, and j melanoma. The approximate location
of unreactive (at background) albumin (Ab) is labeled for comparison.
Approximately 180 non-cancer patient sera were analyzed in parallel
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The epitope of the scFv was that of the original MAB 12.1
and was to ENOX2 in the region of the Glu-Glu-Met-Thr-
Glu drug (capsaicin)-binding motif [8, 12].
Patient sera were from patients with clinically diagnosed
and staged active disease from IRB-approved studies (See
Acknowledgments). Informed consent was used. Non-
cancer comparisons were with sera from healthy volunteers
from the sources indicated and/or from multiple sets of
pooled outpatient sera.
Results
The present report provides a method for the serum analysis
of particular isoforms of the ENOX2 or tNOX (for tumor-
specific NADH oxidase). The method entails 2DGE and
immunoblotting using a recombinant antibody cross reac-
tive with all of the various ENOX2 isoforms which charac-
terize different types of cancers.
Analytical 2DGE of ECTO-NOX enriched serum proteins
from a preparation of sera pooled from carcinoma patients
(cervical, breast, ovarian, prostate, lung, and colon) concen-
trated by nickel agarose precipitation, followed by immuno-
blot analysis revealed multiple protein species in quadrants I
and IV (Fig. 1b) none of which were present in non-cancer
sera (Fig. 1a). With separation in the first dimension by
isoelectric focusing over the pH range of 3–10 and in the
second dimension by 10% SDS-PAGE, a variety of acidic
proteins of molecular weights between 34 and 100 kDa and
absent from non-cancer sera were observed in quadrants I
and IV (Fig. 1b). Isoelectric points of the tNOX isoforms
were in the range pH 3.9 and 6.3. Quadrants II and III of
both cancer and non-cancer patients contained heavy (ca.
52 kDa) and light (ca. 25 kDa) immunoglobulin chains that
were cross-reactive with the recombinant scFv at the
relatively high amounts present in sera (Fig. 1) which
served as convenient loading controls. Albumin and other
serum proteins did not react with the antibody. It is unlikely
that some of the spots with isoelectric points in the pH
range 3.9–6.4, most of which have been identified as
ENOX2 proteins based on capsaicin-inhibited enzymatic
activities, are other proteins that cross react with the anti-
body. Even albumin, a major protein of serum, the ap-
proximate location of which is indicated on all of the gels
to emphasize this point, is completely unreactive.
Sera from individual patients with the various forms of
cancer were analyzed by 2DGE and immunoblotting to
assign each of the ENOX2 isoforms to a cancer of a
particular tissue of origin (Fig. 2). Sera from cervical cancer
patients contained the 94-kDa ENOX2 isoform (Fig. 2a),
sera of ovarian cancer patients contained ENOX2 isoforms
of 80 kDa and 40.5 kDa (Fig. 2b) and sera from patients
with prostate cancer contained one or more 75-kDa ENOX2
isoforms resulting from small variations in isoelectric points
(Fig. 2c). Sera of breast cancer patients contained 64 and
68-kDa ENOX2 isoforms (Fig. 2d), sera from patients with
non-small cell lung cancer contained a 54-kDa ENOX2
isoform (Fig. 2e), and sera from patients with small cell
lung cancer contained a 52-kDa ENOX2 isoform together
with a 40.5-kDa isoform similar to that seen for ovarian
cancer (Fig. 2f). ENOX2 isoforms of Mr 50 and 52-kDa
characterized sera of pancreatic cancer patients (Fig. 2g)
whereas sera of colon cancer patients contain ENOX2
isoforms of 52 and 43 kDa (Fig. 2h). Figure 2i shows
results from sera of a patient with non-Hodgkins lymphoma
illustrating the 45-kDa ENOX2 isoform of low isoelectric
point characteristic of leukemias and lymphomas. Sera of
patients with malignant melanoma contain a ENOX2
isoform of Mr 38 kDa (Fig. 2j).
Results are depicted in a generalized analytical 2-D gel
map of ENOX2 isoforms (Fig. 3) to show corresponding
molecular weights. Isoelectric points together with the
number of patients for which sera were analyzed are
summarized in Table 1. The number of patients ranged
from five (cervical cancer) to more than 70 (prostate
cancer). The results were highly reproducible both with
Fig. 3 2DGE map of ENOX2 isoforms and isoform patterns based on
analyses of sera from patients representing each cancer site analyzed
individually (Fig. 2). Lymphomas and leukemias exhibit isoforms of
40 to 45 kDa with a low isoelectric point (pH 3.9). NSC non-small
cell, NH non-Hodgkins
Clin Proteom (2009) 5:46–51 49
regard to molecular weight (±1 kDa) and isoelectric point
(±0.1 pH unit).
Analyses of breast, non-small cell lung, colon, prostate,
and ovarian carcinoma patients where approximately equal
numbers of tumor grades I through IV were available for
analysis, revealed readily detectable spots even with grade I
suggesting the potential for very early detection. However,
between grade I and grade III, spot size was less than
doubled (spot size doubles with a ca. tenfold increase in
amount of immunoreactive protein based on experiments
with recombinant ENOX2). As a result, the 2DGE system
with detection by western blot analysis does not provide for
precise quantitation of isoform amounts since spot size
varies as the log of protein amount. Comparing 15 patients
with stage I to IV prostate cancer and prostate specific
antigen (PSA) levels between 5 and 250 ng/ml, the spot
diameter and log PSA were correlated (r2=0.7) despite the
log-linear relationship and the relatively low diagnostic
specificity of the PSA [17].
Discussion
2DGE generates cancer-specific isoform patterns and
compositions indicative of cancer presence, tumor type,
disease severity, and possibly therapeutic response. The
protocol resulted in the detection of more than ten cancer-
specific ENOX2 isoforms which are resolved to indicate
cancer presence and tissue of origin. The ENOX2 isoforms
are identified on the basis of their molecular mass and
isoelectric point with detection using an ENOX2-specific
recombinant antibody single chain variable region scFv
fragment expressed in bacteria which recognizes all
ENOX2 proteins. The latter was produced from ENOX2-
specific IgG rescued from ENOX2-specific monoclonal
antibody producing hybridoma cells [12].
Each of the ENOX2 isoforms signaling cervical
(94 kDa), ovarian (80 kDa), prostate (75 kDa), breast
(64–68 kDa), non-small cell lung (54 kDa), leukemia/
lymphoma (45 kDa), and melanoma (38 kDa) is repre-
sented on 2DGE/western blots by ENOX2 antibody-
reactive species of unique molecular weights. Colon,
pancreatic, and small cell lung cancer share a common
isoform of molecular weight 52 kDa. However, with colon
cancer, the 52-kDa isoform is accompanied by a 40.5-kDa
isoform with an isoelectric point of pH 3.9. For pancreatic
cancer, the 52-kDa isoform exhibits an isoelectric point
of pH 3.9 (compared to 4.3 for the 52-kDa isoform of
colon and small cell lung cancer) and is accompanied by
a 50-kDa isoform (Fig. 2g). The 40.5-kDa isoform which
accompanies the 80-kDa isoform indicative of ovarian
cancer appears to be the same or similar to the 40.5-kDa
isoform characteristic of colon cancer. With small cell lung
cancer, no obvious secondary ENOX2 isoform markers
have been observed on any of the 2DGE western blots such
that presence of the 52-kDa ENOX2 isoform and absence
of the 40.5-kDa ENOX2 isoform serves to distinguish
small cell lung from colon cancer.
Comparisons with known amounts of 34 kDa recombi-
nant ENOX2 proteins produced in bacteria were used to
demonstrate that ENOX2 proteins were absent or present at
levels below the limits of detection (less than 10 pmol/ml of
serum) from sera of healthy volunteers or patients with
diseases other than cancer. In contrast, circulating ENOX2
has been detected in sera of more than 500 cancer patients
representing all major forms of human cancer, including
leukemias and lymphomas based on spectrophotometric
measurements [10, 11].
The presence of the ENOX2 protein was earlier dem-
onstrated in a number of human tumor tissues and xeno-
grafts from cytochemical studies [12]. However, serum
analyses had already suggested a much broader association
with cancer. ENOX2 proteins are ectoproteins reversibly
bound at the outer leaflet of the plasma membrane [18]. As
is characteristic of other examples of ectoproteins (sialyl
and galactosyl transferases, dipeptidylamino peptidase IV,
etc.), the ENOX2 proteins are shed [9, 10]. They appear in
soluble form in conditioned media of cultured cells [9], in
patient sera [19] and in patient urine [20]. The ENOX2
isoforms from sera of cancer patients exhibit the same
degree and specificity of inhibition by anti-cancer drugs
(i.e., the EC50 values for inhibition of activity are the same
or similar) as do the membrane-associated forms [10, 11].
In contrast, no drug-responsive NOX activities were found
with sera from healthy volunteers or sera from patients
with diseases other than cancer. As such, the antitumor-
responsive ENOX2 activity represents the first reported
cell surface change undetected from non-cancer cells and
potentially associated with most, if not all, forms of
human cancer. ENOX2 isoform presence at all stages of
cancer progression (I–IV) offer the potential for non-
Table 1 Sera from patients with different cancers exhibit patterns of
ENOX2 isoforms with differing molecular weights and isoelectric
points (pH)
Cancer Number Mr (kDa) pH
Cervical 5 94 5.4
Ovarian 25 80 and 40.5 4.2 and 4.1
Prostate 70 75 6.3
Breast 16 64 to 68 4.5
Non-small cell lung 50 54 5.1
Small cell lung 12 52 4.3
Pancreatic 24 50 and 52 4.3 and 3.9
Colon 52 52 and 40.5 4.3 and 3.9
Lymphoma, leukemia 7 45 3.9
Melanoma 6 38 5.1
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invasive, early detection of cancer as well as the monitoring
of therapeutic response and cancer recurrence and other
diagnostic applications.
The ENOX2 (tNOX) gene is present in the human
genome as a single copy, with no obvious homologs and a
single constitutive ENOX1 (CNOX) ortholog. It is not a
gene mutated in cancer but is universally present. The
ENOX2 splice variants all appear to be variations resulting
from an exon 4 minus splicing event that allows for down-
stream initiation and expression at the cell surface of the
ENOX2 protein only in cancer cells [13]. Without the exon
4 deletion, mRNA derived from the gene does not appear to
be translated into protein.
Analysis of ENOX2 gene transcripts and the results from
the findings with the pan-ENOX2 recombinant antibody
establish that most, if not all, ENOX2 isoforms share a
common region of protein structure of about 25 kDa (230
amino acids) at the carboxy terminus. This region contains
the region of the protein responsible for its functional
enzymatic activities, its response to anticancer drugs (drug-
binding site) and the determinants in exon 5 at or near the
drug-binding site recognized by the recombinant antibody.
These properties are shared by all of the ENOX2 isoforms
recognized on western blots. However, the remainder of the
protein sequence of each of the isoforms must contain
sequences which are unique to that particular isoform to
account for their demonstrated differences in relative
molecular weight and isoelectric point. These sequences
will be available to generate monoclonal or peptide anti-
bodies that recognize only these isoform-specific regions of
the ENOX2 proteins.
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